Compare Palo Alto Networks Inc (PANW) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Palo Alto Networks Inc vs BIO-TECHNE Corp — how do they compare? Palo Alto Networks Inc trades at $418.78 (market cap $331.76B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: Palo Alto Networks Inc is far larger — about 29.2× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Palo Alto Networks Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Palo Alto Networks Inc for 82 Days and BIO-TECHNE Corp for 64 Days on average.
| PANW | TECH | |
|---|---|---|
Market Cap | $331.76B | $11.36B |
Volume | 3,886,927 | 5,390,331 |
Sector | Technology | Health |
52-Week High | $419.91 | $72.61 |
52-Week Low | $141.67 | $43.31 |
Typical Hold Time | 82 Days | 64 Days |
Enterprise Value | $331.19B | $11.39B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Palo Alto Networks trades at $398.50, down 1.7% today but remains near recent highs. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Revenue growth continues at $9.22 billion for 2025, though profitability metrics show mixed results with high gross margins but modest net income margins. The company's AI security initiatives are driving positive media coverage and investor optimism.
Outlook remains positive given strong analyst consensus (72% buy ratings) and AI-driven cybersecurity demand, but premium valuations and execution risks warrant caution. The stock trades near its consensus price target of $398.70, suggesting limited near-term upside without significant earnings acceleration or multiple expansion.
TECH trades at $72.45, near its 52-week high of $72.70 (Defense World, 2026-09-28), with a slight 0.11% decline over 24 hours. The stock shows a bullish technical signal, supported by moving averages, while fundamentals reveal a high P/E of 62.46 and net income margin of 14.97% for 2025. Recent news highlights shareholder approval of its acquisition by Merck KGaA at $73.00 per share (PRNewsWire, 2026-09-23), a key catalyst for near-term price action.
The outlook is mixed: the acquisition offers upside to the current price, but elevated valuation ratios pose risks if earnings growth falters. Analyst consensus is divided with 46% buy ratings, and net income volatility from 2022-2025 signals execution challenges. Investors should weigh the acquisition premium against fundamental sustainability in a competitive life sciences tools sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Palo Alto Networks Inc
Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.
Read more on PANW →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
